|
NEOPROFEN®
(Ovation Pharmaceuticals)
(Ibuprofen Lysine)
The first new pharmaceutical product in 20 years to treat a potentially life-threatening congenital heart defect in premature infants. NeoProfen® (ibuprofen lysine) Injection (10mg/mL) is indicated — when usual medical management is ineffective — to close a clinically significant patent ductus arteriosus (PDA), a condition in which a blood vessel (ductus arteriosus) in the heart fails to close after birth.
|
|
|
Injectables